Iodine-124 scan study for systemic amyloidosis
Part of Hormones & metabolism clinical trials.
This Phase 2 study tests an iodine-based scan medicine to help learn how systemic amyloidosis affects the body and organs. It may help doctors better characterize the disease using specific imaging tests.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have systemic amyloidosis with organ involvement, or you carry a certain transthyretin gene mutation
- Or you have multiple myeloma, or monoclonal gammopathy of undetermined significance (MGUS)
- You are willing to sign consent and complete all study procedures
- You can safely complete the required imaging tests (no severe claustrophobia or other imaging-blocking condition)
- You are not allergic to potassium iodide or gadolinium-based contrast medicine
- Your kidney function is good enough for the heart MRI contrast (eGFR 30 or higher); and you are not on dialysis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a special PET/CT scan (Pan-Amyloid) that finds abnormal protein deposits (amyloid) in the heart and body. It is for people who have or may have cardiac amyloidosis and are already planning to get this scan.
This trial uses a special PET/CT scan to see if a radioactive tracer can measure changes in amyloid buildup in people with CAPS who have developed a skin reaction to anakinra. It may help doctors understand how the disease is affecting your organs.
This trial tests a special scan that uses a radioactive tracer to look for amyloid protein deposits in people who have had surgery for lumbar spinal stenosis (narrowing of the spine in the lower back) or carpal tunnel syndrome. The goal is to see if the scan can detect these deposits, which may be linked to ongoing orthopedic issues.
This study uses PET/CT scans to look at the heart in people who carry a genetic change (TTR mutation) that can cause a heart condition called amyloidosis, and compares them with people who have symptoms and healthy controls. It may help doctors better understand and detect the disease earlier.
This study tests a new PET imaging agent (evuzamitide) to see if it can better detect cardiac amyloidosis when earlier tests were unclear. It may help confirm if the heart problem is related to TTR amyloid and guide further care.
This study tests a new imaging agent (99mTc-p5+14) that helps doctors see amyloid deposits in the body, especially in the heart. It is for healthy volunteers and people with AL or ATTR amyloidosis that has affected the heart.
Hear when a new Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.